New drug trial aims to slow Parkinson's progression
NCT ID NCT05931484
Summary
This study is testing an investigational drug called FHL-301 in adults with early-stage Parkinson's disease. It aims to see if the drug is safe, well-tolerated, and can help control the movement symptoms of the disease. Participants will be randomly assigned to receive either FHL-301 or a placebo for up to 48 weeks, and their motor function will be closely monitored.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.